Clinical Trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Study acronym: CIRCULATE-US
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Protocol Amendment History 3 changes
notable Trial sites expanded: 1063 -> 1066 locations 2026-08-05
notable Trial sites expanded: 1056 -> 1061 locations 2026-06-04
notable Trial sites expanded: 1046 -> 1054 locations 2026-04-03
Trial Details
NCT Number NCT05174169
Lead Sponsor NRG Oncology
Collaborators: Natera, Inc., National Cancer Institute (NCI)
Conditions Stage III Colon Cancer
Enrollment 1,912 participants
Start Date 2022-07-08
Primary Completion 2029-03-10 (estimated)
Study Completion 2030-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04